Rapport Therapeutics, Inc.
RAPP · XNASCIK 2012593fmd_15BD85J42FZSJZ31Y716SNYDF5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 28 | 61 | 95 |
| Total operating expenses | 36 | 83 | 125 |
| Operating income | (36) | (83) | (125) |
| Interest and investment income | 3 | 12 | 14 |
| Other non-operating income (expense) | 1 | 5 | 14 |
| Income before taxes | (35) | (78) | – |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (35) | (78) | – |
| Net income | (35) | (78) | (111) |
| Net income to common shareholders | (35) | (78) | (111) |